Relevance of the immune system in human urological malignancies: Prospective for future clinical treatments

Urology

Volumn 51, Issue 5 SUPPL. A, 1998, Pages 41-49

  Nouri, A M E ^b   Symes, M O ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BETA 2 MICROGLOBULIN; CD40 ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOMYCIN C; MONOCLONAL ANTIBODY; THIOTEPA;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MINIMAL RESIDUAL DISEASE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; URINARY TRACT CANCER;

CELL LINE; CYTOKINES; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0031832224     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00073-9     Document Type: Article

References (106)

1. Zinkernagal R.M., Doherty P.C. MHC cytotoxic T cells studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity . Adv Immunol. 27:1979;51-77.
2. McMichael A.J., Ting A., Zweerink H.J., Askonas B.A. HLA-restriction of cell mediated lysis of influenza virus infected human cells. Nature. 270:1977;524-526.
3. Fleming K.A., McMichael A., Morton J.A., Woods J., McGee J.O.D. Distribution of HLA class I antigens in normal human tissue and in mammary cancer. J Clin Pathol. 34:1981;779-784.
4. Masucci M.G., Torsteindottir S., Colombani J., Bratbar C., Klein E., Klein G. Down-regulation of class I HLA antigens and Epstein-Barr virus encoded latent membrane protein in Burkitt's lymphoma lines. Proc Natl Acad Sci. 84:1987;4567-4571.
5. Heinemann D., Smith P.J.B., Symes M.O. Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinomas. Br J Cancer. 56:1987;433-437.
6. Smith M.E.F., March S.G.E., Bodmer J.G., Gelsthorp K., Bodmer W.F. Loss of HLA A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci. 86:1989;5557-5561.
7. Nouri A.M.E., Smith M.E.F., Crosby D., Oliver R.T.D. Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma. Br J Cancer. 62:1990;603-606.
8. Moller P., Hermann B., Moldenbauer G., Momburg F. Defective expression of MHC class I antigens is frequent in B cell lymphoma of high grade malignancy. Int J Cancer. 40:1987;32-39.
9. Moore D.H., Fowler W.C., Olafsson K. Class I histocompatibility antigen expression a prognostic factor for aneuploid ovarian cencers . Gynecol Oncol. 38:1990;458-463.
10. Durrant L.G., Ballantyne K.C., Armitage N.C., Robbins R.A., Marksman R., Hardcastle J.D., Balswin R.W. Quantitation of MHC antigen expression on colorectal tumors and its association with tumor progression. Br J Cancer. 56:1987;425-432.
11. Nouri A.M.E., Bergbaum A., Lederer E., Crosby D., Shamsa A., Oliver R.T.D. Paired tumor infiltaring lymphocytes (TIL) and tumor cell line from bladder cancer a new approach to study tumor immunology in vitro . Eur J Cancer. 27:1991;608-612.
12. Rosenberg S.A., Abersold P., Corneta, Kasid A., Morfan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topallian S.L., Merino M.J., Culver K., Miller D., Blease M., Anderson W.F. Gene transfer into human immunotherpy of pateints with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction . N Engl J Med. 323:1990;570-578.
13. Oliver RTD: Alpha interferon and spontaneous regression of renal cell carcinoma, In: First International Symposium Immunobiology of Renal Cell Carcinoma. 1990, pp 87.
14. Ratliffe T., Gillen D., Catalona W.J. Requirement of thymus dependent immune response for BCG mediated anti-tumor activity. J Urol. 137:1987;155-158.
15. Hui K., Grosveld F., Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated transformation. Nature. 311:1984;750-752.
16. Lummen G., Goepel M., Mollhoff S., Hinke A., Otto T., Rubben H. Phase II study of interferon gamma verses interleukin 2 and interferon alpha 2β in mestastatic renal cell carcinoma. J Urol. 155:1996;455-458.
17. Choudhury M., Efros M., Mittelman A. Interferons and interleukins in metastatic renal cell carcinoma. Urology. 41:(suppl 1):1993;67-72.
18. Thrasher J.B., Paulson D.F. Prognostic factors in renal cancer. Urol Clin N Am. 20:1993;247-262.
19. Cordon-Cardo C., Fuks Z., Drobnjak M., Moreno E., Isenbach L., Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 51:1991;6372-6380.
20. Luboldt H.J., Kubens B.S., Rubben H., Grosse-Wilde H. Selective loss of huamn leukocte class I allele expression in advanced renal cell carcinoma. Cancer Res. 56:1996;826-830.
21. Beniers A.J.M.C., Peelen W.P., Debruyne F.M.S., Schalken N.J.A. HLA-class I and class II expression on renal tumor xenografts and the relation to sensitivity for a-IFN, gIFN and TNF. Int J Cancer. 48:1991;709-716.
22. Obiri N.I., Tandon N., Puri R.K. Upregulation of intercellular adhesion molecule-1 (ICAM-1) on human renal cell carcinoma cells by interleukin-4. Int J Cancer. 61:1995;635-642.
23. Tomita Y., Nishiyama T., Watanabe H., Fujiwara M., Sato S. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal cell cancer possible significance in host immune responses . Int J Cancer. 46:1990;1001-1006.
24. Goepel M., Rubben H. Adjuvant therapy in renal cancer. World J Urol. 9:1991;232-236.
25. Oliver R.T.D., Nethersell A.B.W., Bottomley J.M. Unexplained spontaneous regression and alpha interferon as treatment for metastatic renal carcinoma. Br J Urol. 63:1989;128-131.
26. Angus R., Collins C.M.P., Symes M.O. The effect of alpha and gamma interferon on cell growth and histocompatibility antigen expression by human renal carcinoma cells in vitro. Eur J Cancer. 29:1993;1879-1885.
27. Gastl G. Effects of human recombinant alpha2-arg-interferon and gamma interferon on human breast cancer cell lines dissociation of anti-proliferative activity and induction of HLA-DR antigen expression . Cancer Res. 45:1985;2957-2961.
28. Morris A.G., Ward G.A., Bateman W.J. Instability of expression of major histocompatibility antigens in fibroblasts expressing activated RAS oncogene constitutive and interferon-induced class I and class II antigens in a series of clonal isolates of murine fibroblasts transformed by V ki-ras . Br J Cancer. 60:1989;211-215.
29. Giacomini P., Aguzzi A., Pestka S., Fisher P.B. Modulation by recombinant alpha and fibroblast beta interferons on the expression and shedding of HLA and tumor associated antigens by human melanoma cells. J Immunol. 133:1984;1649-1653.
30. Eisenkraft B.L., Nanus D.M., Albino A.P., Pfeffer L. Alpha interferon down regulates epidermal growth factor receptors on renal carcinoma relation of cellular responsivness to the antiproliferative action of interferon . Cancer Res. 51:1991;5881-5887.
31. Fujita T., Asano H., Nadie Y., Ono Y., Ohshima S., Suzuki K., Aso Y., Ariyoshi Y., Fukushima M., Ota K. Anti-tumor effects of human hymphoblastoid interferon on advanced renal cell carcinoma. J Urol. 139:1988;256-258.
32. Sarna G., Figlin R., De Kernion J.B. Interferon in renal cell carcinoma. Cancer. 59:1987;610-612.
33. Trump D.L., Ravdin P.M., Borden E.S., Magers C.F., Whisnant K. Interferon alpha-a1 and continous infusion of vinblastine for treatment of advanced renal cell carcinoma. J Biol Response Mod. 9:1990;108-111.
34. Wirth M.P. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am. 20:1993;283-295.
35. Van Der Masse H., Geertsen P., Thatcher N., Jasmine C., Mercatello A., Fossa S.D., Symann M., Stoter G., Nagel G., Israel L., Osksm R., Palmer P., Franks C.R. Recombinant interleukin-2 in metastatic renal cell carcinoma - a European multicenter phase-II study. Eur J Cancer. 27:1991;1583-1587.
36. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber H.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of 283 conecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. JAMA. 271:1994;907-913.
37. Lissoni O., Barni S., Ardizzoia A. Second line therapy with low dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon alpha. Eur J Cancer. 28:1992;92-96.
38. Sleijfer D.T., Jasen R.A.J., Butler J. Phase II study of subutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatients basis. J Clin Oncol. 10:1992;1119-1123.
39. Tourani J.M., Lucas V., Mayeur D., Dufour B., Palma M., Boaziz C., Grise P., Varette C., Pavlovitch M., Pujade-Lavraine E., et al. Subcutaneous recombinant interleuki-2 in out patients with metastatic renal cell carcinoma. Ann Oncol. 7:1996;525-528.
40. Hanninen E.L., Kirchner H., Atzpodien J. Interleukin-2 based home therpay of metastatic renal cell carcinoma risks and benefits in 215 consecutivie single institution patients . J Urol. 155:1996;19-25.
41. Urba W.J., Steis R.G., Longo D.L. Immomodulatory properties and toxicicty of interleukin-2 in patients with cancer. Cancer Res. 47:1987;185-189.
42. Ellis T.M., Creekmore S.P., McMannis J.D. Appearance and phenotypic characterisation of circulating Leu19+ cells in cancer patients receiving recombinant interleukin-2. Cancer Res. 48:1988;6597-6602.
43. Rosenberg S.A., Lotze M.T., Yang J.C. Prospective randomised trial of high dose interleukin-2 alone or in combination with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 85:1993;622-632.
44. Mannel D.N., Flak W. Interferon gamma is required in the activation of macrophages for tumor cytostoxicity. Cell Immunol. 79:1983;396-402.
45. Johnson H.M., Farrar W.L. The role of gamma interferon like lymphokine in the activation of T cells for expression of interleurkin-2 receptors. Cell Immunol. 75:1981;154-159.
46. Einhorn S., Blomgren H., Strander N. Interferon and spontaneous cytotoxicity in man. Acta Med Scand. 204:1978;477-483.
47. Schwartz R., Momburg F., Moldehver G., Dorken B., Schirrmacher V. Induction of HLA class II antigen expression on human carcinoma cell lines by IFNγ Int J Cancer. 35:1985;245-250.
48. Quesada J.R., Kurzrock R., Sherwin S.A., Guttermann J.U. Phase II studies of recombinant human interferon gamma in mestastatic renal carcinoma. J Biol Response Mod. 6:1987;20-27.
49. Rinehart J.J., Young D., Laforge J., Colburn D., Neidmhrt J. Phase I/II trial of recombinant gamma interferon in patients with renal cell carcinoma immunologic and biological effects . J Biol Response Mod. 6:1987;302-312.
50. Garnick M.B., Reich S.D., Maxwell B., Coval-Goldsmith S., Richie J.P., Rudnick S.A. Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol. 139:1988;251-255.
51. Aulitzky W., Gastl G., Aulitsky W.E., Herold M., Kemmler J., Mull B., Friok J., Huber C. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon gamma. J Clin Oncol. 7:1989;1875-1884.
52. Cameron R., McIntosh J.K., Rosenberg S.A. Synergestic anti-tumor effects of combination immunotherapy with recombinant hybrid alpha interferon in the treatment of established hepatic metastases. Cancer Res. 48:1988;5810-5817.
53. Resenberg S.A., Lotze M.T., Yang J.L., Linehan W.M., Seipp C., Calabro S., Karp S.E., Sherr R.M. Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol. 7:1989;1863-1874.
54. Kirchner H., Korfer A., Palmer P.A., Evers P., De Riese W., Knvver-Hopf J., Hadam M., Goldman V., Kranaks C.R., Poilwoda H., et al. Subcutaneous interleukin-2 and interferon alpha 2b in patinets with metstatic renal cancer the German experience . Mol Biother. 2:1990;145-154.
55. Budd G.T., Murthy S., Finke J., Sergi J., Gibson V., Medendrop S., Barna B., Boyett J., Bukowski R.M. Phase I trial of high dose interleukin-2 and interferon alpha-2a in patients with metastatic malignancy. J Clin Oncol. 10:1992;804-807.
56. Yannelli J.R., Hyatt C., McConnell S., Hines K., Jacknin L., Parker L., Sander M., Rosenberg S.A. Growth of tumor infiltrating lymphocytes from human solid carcers summary of a 5 year experience . Int J Cancer. 65:1966;413-419.
57. Bukowski R.M., Sharfam W., Murthy S., Rayman P., Tubbs R., Alexander J., Budd G.T., Sergi J.S., Bauer L., Gibson V., Stanley S., Boyett J., Pontes E., Finke J. Clinical results and characterization of tumor infiltrating lymphocytes with and without interleukin-2 in human metstatic renal cell carcinoma. Cancer Res. 51:1991;4199-4205.
58. Belldegrun A., Pierce W., Kaboo R., Tso C.L., Shav H., Turcillo P., Moldawer N., Golub S., de Kernino J., Figlin R. Interferon-alpha primed tumor infiltrating lymphocytes combined with interleukin-2 and interferon alpha as therapy for metastatic renal cell carcinoma. J Urol. 150:1993;1384-1390.
59. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., Oldham R.K. Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 316:1987;898-905.
60. Blay J.Y., Favrot M.C., Negrier S., Combaret V., Chaouaib S., Mercatello A., Kasmmerlen P., Franks C.R., Philip T. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res. 50:1990;2371-2374.
61. Blay J.Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J.M., Moskovtchenko J.F., Philip T., Favrot M. Serum levels of IL-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res. 52:1992;3317-3322.
62. Atzpodien J., Kirchner H., Hanninen E.L., Deckert M., Fenner M., Poliwoda H. Interleukin-2 in combination with interferon alpha and 5-fluorouracil for metastatic renal cell cancers. Eur J Cancer. 29:(Suppl 5):1993;56-58.
63. Hofmockel G., Langer W., Theiss M., Gruss A., Frohmuller H.G.W. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2 interferon alpha and 5-fluorouracil. J Urol. 156:1996;18-21.
64. Alexander R.B., Fitzgerald E.B., Mixon A., Carter C.S., Jaaobsen M., Cohen P.A., Rosenberg S.A. Helper T cells infiltrating renal carcinomas have the phenotype of activated memory like T lymphocytes. J Immunother. 17:1995;39-46.
65. Janeway C.A., Bottolmy K. Signals and signs for lymphocyte responses. Cell. 76:1994;275-285.
66. Radmayr C., Bock G., Hobisch A., Klocker H., Bartsch G., Thurnher M. Dendritic actigen presenting cells from the peripheral blood of renal cancinoma patients. Int J Cancer. 63:1995;627-632.
67. Hutchinson G.H., Heinemann D., Symes M., Williamson R.C.N. Differential immune reactivity of tumor intrinsic and peripheral blood lymphocytes against autoplastic colorectal carcinoma cells. Br J Cancer. 44:1991;396-402.
68. American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, 1991.
69. England H.R., Paris A.M.I., Blandy J.P. The correlation of T1 bladder tumor history with progression and follow-up requirement. Br J Urol. 53:1981;593-597.
70. Heney N.M., Ahmaed S., Flanagan M.J., Frable W., Corder M.P., Haferman M.D., Hawkins I.R. Superficial bladder cancer progression and recurrence . J Urol. 130:1983;1083-1086.
71. Morales A., Eidinger D., Bruce A.W. Intracavity Bacilus Calmette Guérin in the treatment of superficial bladder tumors. J Urol. 116:1976;180-182.
72. Herr H.W., Laudone V.P. Intravesical therapy for superficial bladder cancer. Cancer Principles in Practical Oncology. 2:1988;1-3.
73. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 19:1992;573-578.
74. Ratliff T.L., Gillen D., Catalona W.J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 137:1987;155-158.
75. Prescott S., James K., Hargreave T.B., Chisholm G.D., Smyth J.F. Intravesical Evans strain BCG therapy quantitive immunohistochemical analysis of the immune responses within the bladder wall . J Urol. 147:1992;1636-1642.
76. Haaff E.O., Catalona W.J., Ratliff T.L. Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol. 136:1983;970-974.
77. de Reijke T.M., De Boer E.C., Kurth K.H., Schamhart D.H.J. Urinary cytokines during intravesical bacillus Calmette Guérin therapy for superficial bladder cancer progressing, stability and prognostic value . J Urol. 155:1996;477-482.
78. Alexandroff AB, Jackson AM, Clinton S, O'Donnell MO, and James K: IL-12 production after BCG immunotherapy of bladder cancer. Ninth International Congress of Immunology, San Francisco, July 23-29, 1995.
79. Jackson A.M., Alexandroff A.B., Kelly R.W., Skibinska A., Esuvaranathan K., Prescott S., Chisholm G.D., James K. Changes in urinary cytokines and soluble intercellular adhesion molecules-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immuotherapy. Clin Exp Immunol. 99:1995;369-375.
80. Ratliff T.L., Ritchey I.K., Yuan J.J.J., Andriole G.L., Catalona W.J. T cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 150:1993;1018-1023.
81. Fidler I.J., Kataoka T., Hanna M.G. A comparison of in vitro cell mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacllus Camette Guérin tumor cured, tumor sensitised, tumor bearing and normal inbred guinea pigs. Cancer Res. 36:1976;4459-4466.
82. Prescot S., James K., Busuttil J., Hargreave T., Chisholm G., Smyth J. HLA DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol. 63:1989;264-269.
83. Sargent E.R., Williams R.D. Immunotherapetic alternatives in superfical bladder cancer. Urol Clin North Am. 19:1992;581-589.
84. Tubaro A., Stoppacciaro A., Velotti F., Bossola P.C., Cusumano G., Vicentini C., De Carli P., Ruco L., Santoni A., Cancrini A., Giuffrida M., Cippitelli M., Palmer P.A., Miano L. Local immunotherapy of superficial bladder cancer by intervesical instillation of recombinant interleukin-2. Eur Urol. 28:1995;297-303.
85. Woodruff M.F.A., Symes M.O. The use of immunologically competent cells in the treatment of cancer experiments with a transplantable mouse tumor . Br J Cancer. 16:1962;707-715.
86. Prichard-Thomas S., Symes M.O. The use of immunologically competent cells from pig mensenteric lymph nodes to treat pulmonary tumors in mice. Cancer Immunol Immunother. 5:1978;129-133.
87. Prichard-Thomas S., Symes M.O. Observations on the effect of radiotherapy followed by injection of pig lymph node cells in reducing the number of pulmonary tumors induced by intravenous injection of tumor cells into isogenic mice. Cancer Immunol Immunother. 5:1978;135-139.
88. Symes M.O., Eckert H., Feneley R.C.L., Lai T., Mitchell J.P., Rober J.B.M., Tribe C.R. Transfer of adoptive immunity by intra-arterial injection of tumor immune pig lymph node cells treatment of recurrent urinary bladder carcinoma after radical radiotherapy . Urology. 12:1978;398-401.
89. Smith M.E.F., Bodmer W.F., Bodmer J.G. Selective loss of HLA-A,B,C locus products in colorectal adenocarcinoma. Lancet. i:1988;823-824.
90. Nouri A., Smith M., Crosby D., Oliver R. Selective and non-selective immunoregulatory molecules (HLA, B, C antigens and LAFA-3) in transitional cell carcinoma. Br J Cancer. 62:1990;603-606.
91. Nouri A.M.E., Hussain R.F., Oliver R.T.D. The frequency of MHC antigen abnormilities in urological tumors and their correction by gene transfection or cytokine stimulation. Gene Therapy. 1:1994;119-123.
92. Oliver R., Crosby D., Nouri A., Scott E., Galazka A. Evluation of the effect of continuous infusion recombinant interleukin-2 on peripheral blood leukocytes of patients with terminal malignancy. Br J Cancer. 60:1989;934-937.
93. Nouri A.M.E., Hyde R., Oliver R.T.D. Clinical and immunological effect of intravesical Interleukin-2 on superficial bladder cancer. Cancer Immunol Immunother. 39:1994;68-70.
94. Nouri A., Lowdel L.M., Entazami Z., Tezabwala B., Good A., Oliver R. Comparison of immunological changes between subcutaneous and intravenous route of administration of IL-2 in cancer patients. Urologia Internationalis. 56:1996;1-5.
95. Harris A., Smith K., Neal D., Feneley J., Hall R. Epidermal growth factor expression correlates with tumor recurrence, stage progression and overall survival in human bladder cancer. Proc Am Assoc Cancer. 29:1988;453-458.
96. Nouri A., Hussain R., Oliver R. Epidermal growth factor-induced protection of tumor cell susceptibility to cytolysis. Eur J Cancer. 31:1995;963-969.
97. Schreiber A., Schlessinger J., Edidin M. Interaction between major histocompatibility complex antigens and epidermal growth factor receptors on human cells. J Cell Biol. 98:1984;725-731.
98. Kluth B., Hess S., Engelmann H., Schafnitzel S., Riethmuller G., Feucht H.E. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 57:1997;819-899.
99. Cardi C., Heaney J.A., Sened A.R., Phillips D.M., Branda M.T., Ernstoff M.S. T cell receptor chain expression on tumor infiltrating lymphocytes from renal cell carcinoma. Cancer Res. 57:1997;3517-3519.
100. Franco J.L., Ghosh P., Wiltrout R.H., Carter C.R.D., Zea A.H., Momozaki N., Ochoa A., Longo D.L., Sayers T.J., Komschlies K.L. Partial degradation of T-cell signal transduction molecules by contaminating granulocyte during protein extraction of splenic T cells from tumor bearing mice. Cancer Res. 55:1995;3840-3846.
101. Ljungberg B., Grankvist K., Rasmuson T. Serum interleukin-6 in relation to acute phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer. 33:1997;1794-1798.
102. Housseu F., Zelisewski D., Roy M., Paradi V., Richon S., Ricour A., Bougaran J., Prapotnich D., Vallancien G., Benoit G., Desportes L., Bedossa P., Herced T., Nidart J.M., Bellet D. MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinoma. Int J Cancer. 71:1997;585-594.
103. Oliver RTD: Are cytokine responses in renal cell carcinoma the product of placebo effect of treatment or true biotherapy? What trials are needed now?. Submitted Eur J Cancer.
104. Akaza H., Iwasaki A., Ohtani M., Ikeda N., Toida I., Koiso K. Expression of antitumor response role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells . Cancer. 72:1993;558-563.
105. Jackson A.M., Alexandroff A.B., Fleming D., Prescott S., Chisholm G.D., James K. Bacillus Calmette-Guérin organisms directly alter the growth of bladder tumor cells. Int J Oncol. 5:1994;697-703.
106. Zhang Y., Khoo H.E., Esuvanathan K. Effects of bacillus Calmette-Guérin and interferon α-2b on human bladder cancer in vitro. Int J Cancer. 71:1997;851-857.